Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
55 results about "Translational efficiency" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Translational efficiency or Translation efficiency, in the context of cell biology, is the rate of mRNA translation into proteins within cells. It has been measured in protein per mRNA per hour. Several RNA elements within mRNAs have been shown to affect the rate. These include miRNA and protein binding sites. RNA structure may also affect translational efficiency through the altered protein or microRNA binding.
Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
ActiveUS20050032730A1Overcome disadvantagesImprove efficiencyAntibacterial agentsVirusesTranslational efficiencyCoding region
The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
Owner:CUREVAC SE
Modification of RNA, Producing an Increased Transcript Stability and Translation Efficiency
ActiveUS20100129877A1Improve stability efficiencyImprove translation efficiencySugar derivativesFermentationTranslational efficiencyCell biology
Owner:JOHANNES GUTENBERG UNIV MAINZ VERTRETEN DURCH DEN PRASIDENTEN
Dinucleotide MRNA cap analogs
ActiveUS8304529B2Increase opportunitiesImprove translationSugar derivativesActivity regulationPyrimidine NucleotidesRibose
Novel cap analogs which are easily synthesized, resulting in high levels of capping efficiency and transcription and improved translation efficiencies are provided. Such caps are methylated at the N7 position of one or both guanosines of the dinucleotide cap as well as at the 3′ position on the ribose ring. Substituent groups on the ribose ring also result in the cap being incorporated in the forward orientation. Also provided are methods useful for preparing capped analogs and using mRNA species containing such analogs are also contemplated herein, as well as kits containing the novel cap analogs.
Owner:APPL BIOSYSTEMS INC
Dinucleotide MRNA CAP Analogs
ActiveUS20100261231A1Increase opportunitiesImprove translationSugar derivativesActivity regulationRibosePyrimidine Nucleotides
Novel cap analogs which are easily synthesized, resulting in high levels of capping efficiency and transcription and improved translation efficiencies are provided. Such caps are methylated at the N7 position of one or both guanosines of the dinucleotide cap as well as at the 3′ position on the ribose ring. Substituent groups on the ribose ring also result in the cap being incorporated in the forward orientation. Also provided are methods useful for preparing capped analogs and using mRNA species containing such analogs are also contemplated herein, as well as kits containing the novel cap analogs.
Owner:APPL BIOSYSTEMS INC
Reengineering mRNA primary structure for enhanced protein production
ActiveUS8853179B2Improve efficiencyImprove protein stabilitySugar derivativesActivity regulationStart codonTranslational efficiency
Described herein are rules to modify natural mRNAs or to engineer synthetic mRNAs to increase their translation efficiencies. These rules describe modifications to mRNA coding and 3′ UTR sequences intended to enhance protein synthesis by: 1) decreasing ribosomal diversion via AUG or non-canonical initiation codons in coding sequences, and / or 2) by evading miRNA-mediated down-regulation by eliminating one or more miRNA binding sites in coding sequences.
Owner:THE SCRIPPS RES INST
Multiple His sequence tag and application of multiple His sequence tag to protein expression and purification
The invention provides a multiple His sequence tag and application of the multiple His sequence tag to protein expression and purification. Specifically, a nucleic acid builder is composed of coding sequences of nHis, catenation sequences (including the codon optimized catenation sequence and the un-optimized catenation sequence) and coding sequences of foreign proteins. By applying the nucleic acid builder to a protein synthesis system, the translation efficiency of target proteins can be improved, and the foreign proteins can be expressed and purified.
Owner:KANGMA SHANGHAI BIOTECH LTD
Gene expression system based on codon translation efficiency
InactiveUS20050196865A1Efficient expressionAnimal cellsOther foreign material introduction processesTranslational efficiencyNucleotide
The present invention discloses a method for modulating the production of a protein from a polynucleotide in a CHO cell by replacing at least one codon of the polynucleotide with a synonymous codon that has a higher or lower translation efficiency in the CHO cell than the codon it replaces, or by introducing into the CHO cell a polynucleotide that codes for an iso-tRNA which limits the rate of production of the polypeptide and which corresponds to a codon of the first polynucleotide. The present invention also discloses the use of a protein-encoding polynucleotide whose codon composition has been modified for enhanced production of the protein in CHO cells.
Owner:THE UNIV OF QUEENSLAND
Modification of RNA, producing an increased transcript stability and translation efficiency
ActiveUS9476055B2Improve efficiencyImprove stabilityVertebrate antigen ingredientsWhole-cell/virus/DNA/RNA ingredientsTranslational efficiency
Owner:JOHANNES GUTENBERG UNIV MAINZ VERTRETEN DURCH DEN PRASIDENTEN
Cyclic RNA and protein production method
The present invention provides a cyclic RNA preferable for carrying out rotary protein translation in which translation domains other than that of the target protein are sufficiently short and translation efficiency is high, and a method for producing protein that uses this cyclic RNA as template. More specifically, the present invention provides a cyclic RNA that encodes a protein, has a full-length number of bases that is equal to or greater than 102 and is a multiple of 3, has at least one start codon, does not have a stop codon in the same reading frame as the start codon, and does not contain an internal ribosome entry site (IRES). In addition, the present invention provides a method for producing protein in a eukaryotic cell expression system that consists of using the aforementioned cyclic RNA as template and expressing a protein encoded by that cyclic RNA.
Owner:RIKEN
DNA fragment for improving translation efficiency, and recombinant vector containing same
InactiveUS20120255069A1Improve translationImprove translation efficiencySugar derivativesOther foreign material introduction processesHeterologousTranslational efficiency
The present invention relates to a DNA fragment for improving translation efficiency, and a recombinant vector containing the same, and more specifically, to a DNA fragment which comprises any one nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6, SEQ ID NOs: 8-10, SEQ ID NOs: 13 and 14 and SEQ ID NO: 16, and improves the translation efficiency of a heterologous protein placed in the downstream, and a recombinant vector containing the DNA fragment. The DNA fragment for improving translation efficiency according to the present invention and a recombinant vector containing the same can improve the translation of a heterologous protein in a transgenic plant. In addition, if a leader polynucleotide inducing the targeting to a particular cellular organelle of a plant is further linked to the recombinant vector in an operable manner, the heterologous protein is targeted to the specific cellular organelle and can be stably accumulated, thereby enabling the mass production of the heterologous protein from the plant.
Owner:HELIX
Carrier for in vitro transcription mRNA, and construction method of carrier, method for obtaining mRNA by carrier transcription and application of carrier
InactiveCN110760535AEfficient in vitro transcriptionAvoid joiningVectorsVector-based foreign material introductionTranslational efficiencyBiochemistry
The invention provides a carrier for in vitro transcription mRNA, and a construction method of the carrier, a method for obtaining mRNA by carrier transcription, and belongs to the technical fields ofmolecular cloning and in vitro transcription. A 5' UTR sequence, a target gene sequence, a 3' UTR sequence and a polyA sequence are connected to the carrier sequentially, and the carrier for in vitrotranscription of the mRNA is obtained. The carrier provided by the invention contains the 5' UTR sequence, the target gene sequence, the 3' UTR sequence and the polyA sequence, so that in vitro transcription of the mRNA can be effectively performed, addition of cap structure analogs is avoided, and the 3' UTR sequence can prolong the half life of translation protein, and the translation efficiency can be improved.
Owner:青岛宁逸生物科技有限公司
Gene expression system based on codon translation efficiency
InactiveUS7901905B2High productImprove efficiencyAnimal cellsOther foreign material introduction processesTranslational efficiencyPolynucleotide
The present invention discloses a method for modulating the production of a protein from a polynucleotide in a CHO cell by replacing at least one codon of the polynucleotide with a synonymous codon that has a higher or lower translation efficiency in the CHO cell than the codon it replaces, or by introducing into the CHO cell a polynucleotide that codes for an iso-tRNA which limits the rate of production of the polypeptide and which corresponds to a codon of the first polynucleotide. The present invention also discloses the use of a protein-encoding polynucleotide whose codon composition has been modified for enhanced production of the protein in CHO cells.
Owner:THE UNIV OF QUEENSLAND
CHO cell strain capable of stably and efficiently expressing recombinant human BMP7 (bone morphogenetic protein-7) and medical application
ActiveCN107164333AGuaranteed stabilityGood compatibilityBone-inducing factorOsteogenic factorBone morphogenetic protein 6Cultured cell
The invention provides a CHO cell strain capable of stably and efficiently expressing recombinant human BMP7 (bone morphogenetic protein-7) and a medical application. A bmp7 gene sequence is constructed by modifying a bmp7 gene of a mouse, a CHO cell serving as a host is also derived from the mouse, the genetic compatibility and the translation efficiency are greatly improved, the defect that gene sequence templates of BMP7 protein expressed by a CHO system are all derived from human bmp7 genes in the prior art is overcome, and the situation that human-sourced gene sequences are difficult to transcribe and translate efficiently by CHO cells due to codon preference is avoided; meanwhile, the adopted CHO-S cells are suspension cultured cells which have been adapted to a serum-free culture medium, the cell strain does not need to be subjected to suspension acclimation, and the engineering CHO cell strain can keep the stability conveniently. The adopted technical means has a remarkable efficiency improvement function in key steps of BMP expression as follows: transcription, translation, folding, conditioned cleavage, secretion, pairing of disulfide bonds and glycoform modification of glycosylation sites.
Owner:长春生物制品研究所有限责任公司
Synthesis and Use of Anti-Reverse Phosphorothioate Analogs of the Messenger RNA Cap
ActiveUS20100233757A1High affinityImprove in vivo stabilitySugar derivativesPeptide/protein ingredients7-MethylguanosineEIF4E
New RNA cap analogs are disclosed containing one or more phosphorothioates groups. The analogs also contain modifications at the 2′-O position of 7-methylguanosine that prevent them from being incorporated in the reverse orientation during in vitro synthesis of mRNA and that hence are “anti-reverse cap analogs” (ARCAs). The ARCA modification ensures that the S atom is precisely positioned within the active sites of cap-binding proteins in both the translational and decapping machinery. The new S-ARCA analogs are resistant to in vivo decapping enzymes. Some S-ARCAs have a higher affinity for eIF4E than the corresponding analogs not containing a phosphorothioate group. When mRNAs containing the various S-ARCAs are introduced into cultured cells, some are translated as much as five-fold more efficiently than mRNAs synthesized with the conventional analog m7GpppG.
Owner:BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV & AGRI & MECHANICAL COLLEGE +1
Method for synthesizing peptides in cell-free translation system
PendingUS20200040372A1Improve translation efficiencySugar derivativesPeptide preparation methodsTranslational efficiencyCell free
An objective of the present invention is to provide methods of synthesizing peptides containing structurally diverse amino acids using cell-free translation systems, which can accomplish excellent translational efficiency as compared to conventional techniques (the conventional techniques being methods which involve preparing aminoacyl-tRNAs which do not have protecting groups outside the translation systems without using ARS, and then adding the prepared aminoacyl-tRNAs into translation systems). In the present invention, it was found that amino acid-containing peptides can be synthesized efficiently by protecting an amino acid linked to tRNA with an appropriate protecting group, and then performing the step of deprotecting the protecting group of the amino acid linked to tRNA and the step of peptide translation from a template nucleic acid in a cell-free translation system in parallel.
Owner:CHUGAI PHARMA CO LTD
Production method for noncyclic peptide-nucleic acid complex having, at n-terminal, amino acid with thiol group near amino group, library thereof, and cyclic peptide-nucleic acid complex library derived from same
PendingUS20190338050A1High yieldHigh puritySugar derivativesPeptide preparation methodsCyclic peptideTranslational efficiency
When the initiation suppression method was used for translation of a peptide having at its N terminus an amino acid residue carrying a thiol group near its amino group with specific protecting groups being introduced to the thiol group and the amino group, it was found that not only the probability of initiation of amino acid translation reaction was improved, but also production of cleaved peptides was suppressed and translation efficiency and purity were improved. Furthermore, it was found that it is possible to efficiently promote the cyclization reaction of the peptide through amide bond formation. Based on these findings, the inventors discovered novel methods for preparing complexes between nucleic acids and peptides containing various unnatural amino acids and having an amide bond-mediated cyclized portion.
Owner:CHUGAI PHARMA CO LTD
Establishment of self-activated Gal4/UAS system expression cassette capable of improving gene expression
ActiveCN107760707AHigh expressionIncrease transcriptionVectorsVector-based foreign material introductionTranslational efficiencyBinding domain
The invention discloses establishment of a self-activated Gal4 / UAS system expression cassette capable of improving gene expression. The expression cassette with good improvement effect is obtained byoptimizing the number of UAS and the types of GAL 4 activation / binding domains; the expression cassette is started by the strong promoter CMV of the expression cassette and improves transcription andtranslation efficiency in virtue of a Gal4 / UAS system, so the effects of automatic activation and cascade amplification are obtained; high improvement effect is maintained in 5 to 10 days after transfection, and highest expression activity is obtained in the eighth day, so it is proved that the expression cassette can improve the stability of gene expression; and improvement effect is about 9 times better in CHO cells specially producing recombinant proteins. Compared with conventional gene expression cassettes, the expression cassette provided by the invention is simple in structure and substantial in improvement effect, and provides an approach and novel method for non-virus transfection approaches of gene therapy and enhancement of the expression of target genes in production of recombinant proteins.
Owner:NORTHWEST A & F UNIV
Code translation method, device and equipment
In order to solve the problems that code cross-platform translation efficiency is low, requirements for translators are high, and translation cost is increased, the invention provides a code translation method which comprises the steps that a first code is obtained, the first code is written based on a platform-dependent language of a source platform, then at least one translation rule matched with the first code is determined, and the first code is translated according to the at least one translation rule. The translation rule is used for directly translating a code of one platform into a code of another platform, and then translating the first code by using the translation rule to obtain a second code suitable for the target platform. According to the method, automatic cross-platform translation of the codes is realized through the translation rule, and the translation efficiency and the translation precision are improved.
Owner:HUAWEI TECH CO LTD
Expression box capable of efficiently achieving secretory expression of human FGF21 protein and application of expression box
ActiveCN109988802AImprove soluble expression and secretion capacityEase of industrial applicationBacteriaMicroorganism based processesProtein targetSecretory protein
The invention belongs to the technical field of molecular biology and particularly relates to a method for efficiently expressing a recombinant human fibroblast growth factor 21 (rhFGF21) gene by using bacillus subtilis. Firstly, the method adjusts the transcription and translation efficiency of a target protein gene by adding different types of cistron sequences to the 5' end of the target protein gene so as to optimize the soluble expression level of the protein gene, and the method can be applied to the optimal expression of different types of heterologous protein; secondly, the method further optimizes disulfide bond related genes to construct a vector to promote the disulfide bond folding efficiency of rhFGF21, overexpresses a molecular chaperone system to construct a vector suitablefor the folding efficiency increasing of rhFGF21 protein, and knocks out various extracellular protease genes to construct a bacillus subtilis gene engineering strain for improving the extracellular stability of rhFGF21; and finally, the method provides a bacillus subtilis gene engineering strain with good application prospect and capable of achieving efficient secretory expression of the rhFGF21protein.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
Method for improving stability of in-vitro synthetic mRNA
PendingCN110218753AImprove translation efficiencyExtend the time of expressionFermentationT7 RNA polymeraseTranslational efficiency
The invention discloses a method for improving the stability of in-vitro synthetic mRNA. After PCR tailing, cap structure analogue modification and base analogue modification are carried out respectively with a luciferase mRNA synthesis template plasmid as a template, the mRNA is synthesized by using an MEGAscript T7 kit according to an instruction book under the action of T7 RNA polymerase. Through researches about the length of polyA tails and the translation efficiency and stability of cap structure analogues and base analogues on the in-vitro synthetic mRNA, it is found that through a series of modification, the translation efficiency of the in-vitro synthetic mRNA in cells can be improved, and the expression time can be prolonged.
Owner:湖北爱济莱斯生物科技有限公司
RNA vaccine for treating non-small cell lung cancer and construction method thereof
PendingCN112501201AImprove stabilityImprove translation efficiencyTumor rejection antigen precursorsTumor specific antigensVaccine StabilityNucleotide
The invention provides an RNA vaccine for treating non-small cell lung cancer. The nucleotide sequence of the RNA vaccine is shown as SEQ ID NO. 1. The RNA vaccine comprises two parts, namely a basicskeleton sequence (backstone) and a tandem vaccine sequence. The invention further provides a construction method of the RNA vaccine for treating the non-small cell lung cancer. According to the RNA vaccine for treating the non-small cell lung cancer, provided by the invention, a nucleotide sequence of a new antigen is optimally designed by utilizing a codon, connection is carried out by utilizinglinker, insertion of sequences such as SEC and MITD and construction of poly A tails are perfected, plasmids are constructed after sequence design is finished, and a target RNA sequence, namely the new antigen RNA vaccine, is obtained through linearization and in-vitro transcription. The vaccine is good in stability, high in translation efficiency and good in treatment effect, and expression products are easy to transfer.
Owner:WUXI PEOPLES HOSPITAL
Method for detecting effect of 3' untranslated region on mRNA translation efficiency
InactiveCN105483155ABiological testingVector-based foreign material introductionFluorescent proteinGene carrier
The invention relates to a method for detecting effect of a 3' untranslated region on mRNA translation efficiency by quantifying transcripts and protein yield in cells at the same time through a dual-fluorescence reporter system, and belongs to the field of molecular biology. The dual-fluorescence reporter gene vector is created, a coding fluorescent RNA molecular sequence is inserted behind a fluorescent protein coding region, then the searched 3' UTR sequence is inserted between the two, a recombinant vector performs transient transfection of cells, quantitative fluorescence analysis is carried out on transcript and protein expression quantity in an imaging culture medium at the same time, and the effect of the 3' UTR on the translation efficiency is judged by comparing fluorescence intensities.
Owner:RES INST OF SUN YAT SEN UNIV & SHENZHEN
Method for carrying out protein translation by using circular RNA and application of circular RNA
The invention provides a method for carrying out protein translation by using circular RNA and an application of the circular RNA. Particularly, the invention provides a circular RNA construct. The circular RNA construct has a structure as shown in a formula I of TI-Z1-Z2 (I) in the 5'-3' direction; in the formula, TI is a translation initiation element, Z1 is an expression cassette expressing foreign protein, and Z2 is none or other element. The circular RNA construct can significantly enhance the translation efficiency in vivo and in vitro.
Owner:SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI
Reengineering mrna primary structure for enhanced protein production
Described herein are rules to modify natural mRNAs or to engineer synthetic mRNAs to increase their translation efficiencies. These rules describe modifications to mRNA coding and 3' UTR sequences intended to enhance protein synthesis by: 1) decreasing ribosomal diversion via AUG or non-canonical initiation codons in coding sequences, and / or 2) by evading miRNA-mediated down-regulation by eliminating one or more miRNA binding sites in coding sequences.
Owner:THE SCRIPPS RES INST
Construct system and uses therefor
InactiveUS20120040367A1Improve preferenceHigh sensitivitySsRNA viruses negative-senseAntibacterial agentsBiological bodyTranslational efficiency
The present invention discloses construct systems and methods for comparing different iso-accepting codons according to their preference for translating RNA transcripts into proteins in cell or tissues of interest or for producing a selected phenotype in an organism of interest or part thereof. The codon preference comparisons thus obtained are particularly useful for modifying the translational efficiency of protein-encoding polynucleotides in cells or tissues of interest or for modulating the quality of a selected phenotype conferred by a phenotype-associated polypeptide upon an organism of interest or part thereof.
Owner:CORIDON
Method of constructing a synthetic polynucleotide
A method of constructing a synthetic polynucleotide, the method including selecting a first codon of a parent polynucleotide that encodes a polypeptide for replacement with a synonymous codon, wherein the synonymous codon is selected on the basis that it exhibits a higher translational efficiency in an epithelial cell of a mammal than the first codon in a comparison of translational efficiencies of codons in test cells of the same type as the epithelial cell; and replacing the first codon with the synonymous codon to construct the synthetic polynucleotide.
Owner:THE UNIV OF QUEENSLAND
DNA fragment to promote translation reaction and method for cell-free protein synthesis system using the same
InactiveUS20060121560A1Promote cloningImprove translation efficiencyAnimal cellsPeptidesTranslational efficiencyA-DNA
The present invention provides a DNA fragment allowing easy cloning of a desired gene and capable of further improving translation efficiency, a protein expression vector and a template DNA having the DNA fragment, a mRNA obtained from the template DNA, a reaction solution for cell-free protein synthesis system containing the template DNA or the mRNA, a method for cell-free protein synthesis system using the template DNA, and, kit for cell-free protein synthesis system including the expression vector. A DNA fragment having the base sequence represented by any of SEQ ID No. 1 to 11 to use for promoting translation reaction, a protein expression vector and a template DNA having the DNA fragment, a mRNA obtained from the template DNA, a reaction solution for cell-free protein synthesis system containing the template DNA or the mRNA, a method for cell-free protein synthesis system using the template DNA, and, kit for cell-free protein synthesis system including the expression vector.
Owner:SHIMADZU CORP
Expression vector for animal cell as well as preparation method and application of expression vector
ActiveCN104694568AReduce translation efficiencyIncrease productionVector-based foreign material introductionForeign genetic material cellsTranslational efficiencySusceptibility/Resistance Gene
Owner:SHENZHEN INST OF ADVANCED TECH
Scanning translation method and device, scanning pen and related product
PendingCN112651248AImprove translation efficiencyImprove translation performanceNatural language translationPictoral communicationTranslational efficiencyComputer graphics (images)
Owner:IFLYTEK CO LTD
Leader sequence for improving non-cap-dependent translation efficiency and application thereof
PendingCN114807145AHigh expressionNucleic acid vectorImmunoglobulinsTranslational efficiencyInternal ribosome entry site
The invention provides a leader sequence for improving non-cap-dependent translation efficiency and application of the leader sequence, and belongs to the technical field of genetic engineering. The leader sequence is as shown in SEQ ID NO. 1. According to the present invention, with the leader sequence, the expression quantity of the target gene mediated by the non-cap-dependent internal ribosome entry site (IRES) element in the transient mammalian cell expression system can be effectively improved;
Owner:XINXIANG MEDICAL UNIV +1
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com